UNSPSC 51422404: Butixocort

This classification denotes a therapeutic glucocorticoid with the molecular formula C25H36O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5D0M4JI29K, chemically known as 11 beta,17-dihydroxy-21-mercaptopregn-4-ene-3,20-dione 17-butyrate. but generally known as butixocort, which bears US NIH Compound Identifier 189904. Butixocort most often comes in base and 21-propionate forms. European Medicines Agency schedules Butixocort in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06023MIG.

UNSPSC 51422404 Butixocort is a Commodity code that state and local health agencies are using to procure pharmaceutical products and related health-system supplies, though recent opportunities show substantial misalignment between the code's nominal scope and actual procurement activity. Seminole County, Florida solicited naloxone and drug deactivation systems through IFB 60459723LAS, requesting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building. The Texas Health and Human Services Commission posted RFI HHS0017013 to gather market intelligence on direct-to-manufacturer prescription fulfillment programs serving state employee health plans and self-insured groups, signaling a shift toward vendor partnerships that bypass traditional pharmacy benefit managers and group purchasing organizations. Issuing bodies under this code span state health authorities and county public health departments pursuing both pharmaceutical procurement and program-level pharmacy benefit restructuring.

Activity concentrates in Florida and Texas, with the most recent opportunities spanning June through April 2026. Seminole County's IFB, posted June 30, 2026 with a response deadline of July 26, 2023, requires vendors to provide electronic bids including all shipping and delivery costs, comply with drug-free workplace and E-Verify requirements, and maintain workers' compensation and liability insurance; the contract runs two years with a one-year renewal option and includes a three-month probationary termination clause. Texas HHS's RFI, posted April 3, 2026, seeks vendor experience with direct contracting for self-insured employers in both private and government sectors within the past two years and capability to negotiate net-pricing models outside traditional GPO and wholesaler arrangements, with no award value, timeline, or set-aside designation specified at the information-gathering stage. The code shows limited recent activity overall, and the opportunities posted diverge significantly from butixocort (a corticosteroid pharmaceutical) — neither solicitation explicitly names that product class.